Regeneus Ltd Health Care
Biotech Healthcare

$0.007 (0%)

High $0.01	Low $0.01	Trades 6	Turnover $9,683	Volume 1,383,303
30 June 2023 at 3:17pm

Market Cap (29-Apr) $3,677,244 (1,574th)	Close (30-Jun) $0.007 0 (0%)	Volume (30-Jun) 1,383,303	Shortsold (6-Feb) 60,198 (0.02%) (486th)
52w High $0.018	52w Low $0.003	P/E -	EPS 0

Short Interest

ASIC data, 6 Feb 2020

% Shorted

0.02%

Most Shorted Rank

486th

of 716 shorted ASX stocks

Peak Short

0.02%

Feb 2020

Days to Cover

0.1

at 50d avg vol

View full short position history →

	Subject
	RGS RGS Ann: Appendix 4E - Preliminary final report-unaudited
	1 (current) 2 3
	RGS RGS Ann: Date of AGM
	RGS RGS Ann: Lapse of Unlisted Share Options - correction
	RGS RGS Ann: Notification of cessation of securities - RGS
	RGS RGS Ann: Lapse of Unlisted Share Options
	RGS RGS Ann: Quarterly Activities/Appendix 4C Cash Flow Report
	RGS RGS Ann: R&D Collaboration with Kolling Institute
	RGS RGS Ann: Company Secretary Appointment/Resignation
	RGS RGS Ann: Appendix 2A
	RGS RGS Ann: Cleansing Statement
	RGS RGS Ann: Proposed issue of Securities - RGS
	RGS RGS Ann: Regeneus Announces Institutional Placement
	RGS RGS Ann: Grant of Options to CEO and Appendix 3G
	RGS RGS Ann: Appendix 4C - Quarterly
	RGS RGS Ann: Regeneus partners with Defence to treat combat casualties
	RGS RGS Ann: Regeneus to be granted key Progenza patent in Europe
	RGS RGS Ann: Regeneus Company Update Investor Webcast Presentation
	RGS RGS Ann: Appendix 3Z Final Director's Interest Notice Dr Alan Dunton
	RGS RGS Ann: Half-Year Results and Business Update
	RGS RGS Ann: Appendix 4D and Half-Year Report
	RGS RGS Ann: Regeneus Company Update Investor Webcast Notification
	RGS RGS Ann: Resignation of Non Executive Director Dr Alan Dunton
	RGS RGS Ann: Regeneus to be granted new patent to target pain in Japan
	RGS RGS Ann: Response to ASX Appendix 4C Query
	RGS RGS Ann: Clarification on Quarterly Activity Report and Appendix 4C
	RGS RGS Ann: Appendix 4C - Quarterly Report
	RGS RGS Ann: Lapse of Unlisted Share Options
	RGS RGS Ann: Appendix 3Y - Leo Lee
	RGS RGS Ann: Appendix 3Y - Alan Dunton
	RGS RGS Ann: Appendix 3Y - John Chiplin
	RGS RGS Ann: Appendix 3Y - Graham Vesey
	RGS RGS Ann: Clarification on Quarterly Activity Report and Appendix 4C
	RGS RGS Ann: Material Terms of Contract for Chief Executive Officer
	RGS RGS Ann: CEO Appointment and Resignation
	RGS RGS Ann: Annual Report Additional Information
	RGS RGS Ann: Appendix 4C - Quarterly
	RGS RGS Ann: Regeneus receives $5.6M milestone payment from Kyocera

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

Telix Pharmaceuticals

TLX

End of Day Prices

Date	Close	Volume	Change
29-Apr	$0.01	0	0.00 (0.00%)
26-Apr	$0.01	0	0.00 (0.00%)
24-Apr	$0.01	118,641	+0.00 (12.50%)
23-Apr	$0.01	0	0.00 (0.00%)
22-Apr	$0.01	50,000	0.00 (0.00%)
19-Apr	$0.01	200,000	0.00 (11.11%)
18-Apr	$0.01	0	0.00 (0.00%)
17-Apr	$0.01	0	0.00 (0.00%)
16-Apr	$0.01	680,975	+0.00 (12.50%)
15-Apr	$0.01	2,433,855	0.00 (20.00%)
12-Apr	$0.01	755,915	0.00 (23.08%)
11-Apr	$0.01	1,767,281	0.00 (7.14%)
10-Apr	$0.01	459,764	+0.00 (16.67%)
09-Apr	$0.01	4,275,678	+0.00 (33.33%)
08-Apr	$0.01	1,683,175	0.00 (30.77%)
4 up, 5 down, and 6 flat days

Regeneus Ltd Health Care
Biotech Healthcare

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Regeneus Ltd Health Care Biotech Healthcare

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Regeneus Ltd Health Care
Biotech Healthcare